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Abstract
 
T lymphocytes expressing the T cell receptor (TCR)-
 
  
 
 recognize unknown antigens on tumor
cells. Here we identify metabolites of the mevalonate pathway as the tumor ligands that activate
TCR-
 
  
 
 cells. In tumor cells, blockade of hydroxy-methylglutaryl-CoA reductase (HMGR),
the rate limiting enzyme of the mevalonate pathway, prevents both accumulation of mevalonate
metabolites and recognition by TCR-
 
  
 
 cells. When metabolite accumulation is induced by
overexpressing HMGR or by treatment with nitrogen-containing bisphosphonate drugs, tumor
cells derived from many tissues acquire the capacity to stimulate the same TCR-
 
  
 
 population.
Accumulation of mevalonate metabolites in tumor cells is a powerful danger signal that activates
the immune response and may represent a novel target of tumor immunotherapy.
Key words: antigen recognition • tumor antigen • HMGR • IPP • bisphosphonate drugs
 
Introduction
 
Human T cells expressing the TCR-
 
  
 
 represent a unique
lymphocyte population with an unusual tissue distribution.
These cells are present in both organized lymphoid tissues
as well as in the skin- and gut-associated lymphoid systems
without any special tropism for epithelia (1). Information
has been accumulating regarding the microbial antigens
they recognize. A series of small phosphorylated nonpep-
tidic metabolites which stimulate the V
 
 
 
9/V
 
 
 
2 population
have been identified. Amongst these isopentenylpyrophos-
phate (IPP)
 
*
 
 is a prototype ligand (2, 3). Some of these
ligands were purified from microbial cells and are interme-
diate metabolites of farnesylpyrophosphate (FPP) synthesis
(4, 5). These products are essential for cell survival and are
ubiquitous. Therefore, this unique type of antigen specific-
ity was suggested to be best suited for activation of “senti-
nel” cells independently of any unique antigens derived
from individual microbes (6).
An important aspect of antigen specificity of human
TCR-
 
  
 
 cells is their capacity to recognize and kill tumor
targets. T cells expressing the V
 
 
 
9/V
 
 
 
2 heterodimer, the
same TCR stimulated by bacterial phosphorylated metabo-
lites, recognize bone marrow–derived tumor cells such as
the non-Hodgkin B cell lymphoma line Daudi both in
vitro (7) and in a SCID animal model in vivo (8). TCR
V
 
 
 
9/V
 
 
 
2 also recognize and kill the B cell lymphoma
RPMI-8233 (9), the T cell lymphoma MOLT-4 (10) and
the erythroleukemia line K562 (11). In no case has the acti-
vating ligand been identified.
To identify the tumor antigens which activate V
 
 
 
9/V
 
 
 
2
cells, we tested the hypothesis that in tumor cells TCR-
 
  
 
cells recognize phosphorylated nonpeptidic ligands resem-
bling those produced by microbial cells. This hypothesis
was prompted by the reported increased expression and
function of HMGR, the rate limiting enzyme in the meval-
onate pathway (Fig. 1) in haematological malignancies (12)
and mammary carcinoma cells (13). Mevalonate pathway
dysregulation in tumor cells might lead to accumulation of
phosphorylated mevalonate metabolites and activation of
V
 
 
 
9/V
 
 
 
2 cells. Most of the studies herein were performed
using Daudi cells. We also found that a breast carcinoma
line (YMB-1) activates the V
 
 
 
9/V
 
 
 
2 population using the
same mechanism as Daudi cells.
 
Materials and Methods
 
Chemicals.
 
IPP, mevastatin, 7-dehydrocholesterol (7-DHC),
farnesol, and monensin (Mon) were purchased from Sigma-
Aldrich. Zoledronate (ZOL), C
 
14
 
-labeled ZOL, pamidronate
 
The online version of this paper contains supplemental material.
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Abbreviations used in this paper:
 
 FPP, farnesylpyrophosphate; IPP, iso-
pentenylpyrophosphate; PAM, pamidronate;
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(PAM), and etidronate were supplied as hydrated disodium salts
by Novartis. PHA was purchased from Murex Biotech, 
 
3
 
H-IPP
from ARC.
 
Cells.
 
The following cell lines were used: A-375 cells, a ma-
lignant melanoma; A-431, an epidermoid cancer; Daudi, a Bur-
kitt’s lymphoma; THP-1, a monocytic leukemia; CEM 1.3, a T
cell lymphoma; Colo 201, a coloncarcinoma line; HEP-G2 a
hepatocarcinoma and K562 an erythroleukemia line all obtained
from American Type Culture Collection. YMB-1, HMC-1–8,
and MRK-nu-1 mammary carcinomas were obtained from
Health Science Research Resources Bank, Osaka, Japan. Primary
human lung fibroblasts were obtained from M. Bihl; hepatoblas-
toma cell line HuH6 (E. Köhler); glioblastomas U118 and
BS125.3.2 (A. Merlo; all from University Hospital, Basel, Swit-
zerland); astrocytoma A-243 was established from an anaplastic
astrocytoma (WHO grade III). TCR V
 
 
 
9/V
 
 
 
2 T cell clones
were obtained, cultured, and restimulated as described (10). Tu-
mor and primary cells were cultured as described (10). Most of
the experiments were performed with more than one TCR
V
 
 
 
9/V
 
 
 
2 T cell clones, always showing similar results and were
done at least three times. Activation assays with ZOL were per-
formed using a large panel of previously described TCR-
 
  
 
clones (10), (online supplemental Table S1). These experiments
confirmed that a TCR composed of V
 
 
 
9-C
 
 
 
1 and V
 
 
 
2 chains is
required for recognition of Daudi cells or for ZOL-pulsed APCs.
 
T Cell Stimulation Assays.
 
Cells used as stimulatory APCs
were incubated with different doses of bisphosphonates for 3 h at
37
 
 
 
C or at 4
 
 
 
C followed by three washes before plating (5 
 
 
 
 10
 
4
 
/
well) and subsequent addition of T cells (5 
 
 
 
 10
 
4
 
/well). In some
 
experiments mevastatin (25 
 
 
 
M) was added 2 h before bisphos-
phonates and again after removal of bisphosphonates to maintain
a constant concentration during incubation with T cells. Farnesol
and 7-DHC were pulsed on APC for 12 h and rinsed out before
addition of T cells. Stimulation with IPP (10 
 
 
 
M) and PHA (1
 
 
 
g/ml) served as positive controls to exclude unspecific or toxic
effects of the tested drugs. To study the kinetics of activation in-
duced by nitrogen-containing bisphosphonate drugs (nBP),
Daudi cells were pulsed with 50 
 
 
 
M PAM or ZOL for selected
periods (1–18 h), washed three times, and incubated with TCR-
 
  
 
 T cell clone G2B9 for 12 h.
 
TNF
 
 
 
 Release Assay.
 
APC (5 
 
 
 
 10
 
4
 
/well) and T cells (5 
 
 
 
10
 
4
 
/well) were incubated in 96-well plates (BD Biosciences) in
triplicate for 12 h. Ligand and drug concentrations used are indi-
cated in the figure legends. TNF
 
 
 
 released into the supernatant
was measured by ELISA (Immunokontakt) and is expressed as
mean pg/ml or ng/ml 
 
 
 
 SD.
 
14
 
C-ZOL Uptake.
 
Daudi cells were pulsed with 
 
14
 
C-ZOL
(25 
 
 
 
g/ml, corresponding to 700 nCi/ml) for 3 h at 37
 
 
 
C or at
4
 
 
 
C, and washed thrice. Some experiments included monensin
(20 
 
 
 
M) and NaN
 
3
 
 (0.05%) during the ZOL pulse. Radioactivity
incorporated into 10
 
6
 
 cells was counted using scintillation liquid
(IRGA-SAFE PLUS, Packard Bioscience BV) and a 
 
 
 
-counter
(TR 1900, Canberra Packard). Triplicate samples were evaluated.
 
Immunoprecipitation and Western Blotting.
 
Daudi cells (2 
 
 
 
10
 
7
 
/group) either untreated or treated with 7-DHC (100 
 
 
 
g/ml)
or farnesol (50 
 
 
 
M) were lysed and immunoprecipitated with
anti-HMGR rabbit polyclonal antiserum (gift of R. Simoni,
Stanford University, Palo Alto, CA) using protein G-Sepharose
(Amersham Biosciences). Western blotting, after SDS-separation
was performed according to standard protocols. Blots were se-
quentially incubated with anti-HMGR A9 mAb (American Type
Culture Collection) and goat anti–mouse horseradish peroxidase-
conjugated Ig (Southern Biotechnology Associates, Inc.) and
HMGR detected using chemiluminescence substrate (Supersig-
nal; Pierce Chemical Co.).
 
Mevalonate Pathway Assay.
 
Daudi cells (5 
 
 
 
 10
 
8
 
) were lysed
according to reference 14. Cell lysates were concentrated four
times using Biomax-10K filters (Millipore) and 125 
 
 
 
l aliquots
were incubated for 60 min at 37
 
 
 
C under conditions described
(14) in a total volume of 500 
 
 
 
l. The reaction was stopped by ad-
dition of an equal volume of methanol and cooling on ice. The
sample was clarified by centrifugation at 9,000 rpm and stored at
 
 
 
20
 
 
 
C until HPLC separation or phosphatase treatment. HPLC
separation was performed as reported (14) with some modifica-
tions. Briefly, a Spherisorb SAX 5
 
 
 
 HPLC column (4.6 mm 
 
 
 
25 cm; VDS Optilab) was used together with the buffers de-
scribed in reference 14. The gradient was 0–2 min 0% B, 2–13.5
min 57% B, 13.5–14.5 min 99% B, 14.5–35 min 99% B. Radio-
activity was detected online with a 
 
 
 
 scintillation detector (Pack-
ard Instrument Co.) using Ultima Flo M (Packard Instrument
Co.) as scintillant. UV monitoring (254 nm) was also applied.
Separate HPLC runs under identical conditions were performed
using material obtained by incubation with nonradioactive me-
valonate. Fractions were collected every 15 s and examined in T
cell activation assays. Active fractions were further analyzed by
mass spectrometry. Fractions were lyophilized and tested at a final
dilution of 1:12 using 5 
 
 
 
 10
 
4
 
/well THP-1 cells as APCs and
5 
 
 
 
 10
 
4
 
/well G2B9 TCR-
 
  
 
 T cells. Released TNF
 
 
 
 was mea-
sured by ELISA. In some experiments Daudi cell extract was
treated with alkaline phosphatase as described (15).
 
Generation of HMGR Stable Transfectants.
 
Hamster HMGR
cDNA (pRed-227; American Type Culture Collection) was sub-
Figure 1. Mevalonate metabolic pathway. The compounds used in this
study and the affected enzymes are indicated in frames.T
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cloned into the XhoI/NotI sites of the BCMGSNeo expression
vector. Daudi cells were transfected with 10 
 
 
 
g DNA by elec-
troporation, and selected using G418 (Calbiochem).
 
Intracellular HMGR Staining of Transfected Cells.
 
Daudi cells
fixed with 2% paraformaldehyde were incubated for 30 min with
biotinylated mouse anti-HMGR A9 mAb or isotype-matched ir-
relevant mAb in PBS containing 0.1% saponin, revealed with
phycoerythrin-coupled Streptavidin (Southern Biotechnology
Associates, Inc.), and analyzed using a FACScan™ and the
CELLQuest program (BD Biosciences).
 
Mass Spectrometry Analysis.
 
After desalting, samples were dis-
solved in 10 
 
 
 
l of 50% methanol. A few microliters were loaded
into a nanospray tip (Protana Engineering A/S). The spray was
initiated at a voltage of 1,100 V. Spectra were recorded on a
Finnigan TSQ7000 instrument (Finnigan) in negative ion mode
set to 1 D resolution.
 
Online Supplemental Material.
 
Online supplemental ma-
terial is available at http://www.jem.org/cgi/content/full/
jem.20021500/DC1. 
 
Results and Discussion
 
We found that YMB-1 cells, a solid breast carcinoma,
activate the same V
 
 
 
9/V
 
 
 
2 population as that stimulated
by Daudi Burkitt’s lymphoma cells. To test the role of
HMGR in generating TCR-
 
  
 
 stimulatory ligands, both
Daudi and YMB-1 cells were treated with mevastatin, an
inhibitor of the HMGR catalytic site (16). Mevastatin
treatment of both cell lines efficiently inhibited activation
of TCR-
 
  
 
 cells expressing the TCR V
 
 
 
9/V
 
 
 
2 (Fig. 2 A).
In control experiments, the same T cell population was not
inhibited when stimulated with exogenous IPP or with
PHA in the presence of mevastatin, thus excluding a toxic
effect of the drug (Fig. 2 A). Involvement of HMGR was
further investigated by treating Daudi cells with 7-DHC or
farnesol, two endogenous metabolites that facilitate degra-
dation of HMGR by a negative feedback mechanism (17,
18). Both compounds reduced intracellular levels of
HMGR protein as shown by immunoprecipitation and
Western blotting (Fig. 2 B), and significantly inhibited the
capacity of Daudi cells to activate TCR-
 
  
 
 cells (Fig. 2 C).
In control experiments neither compound modified TCR-
 
  
 
 response to IPP, thus excluding nonspecific toxic effects
(Fig. 2 C). Taken together these experiments show that
HMGR is a key player in the stimulation of TCR-
 
  
 
 lym-
phocytes by Daudi and YMB-1 cells, and suggest that
phosphorylated metabolites generated in the mevalonate
pathway are the stimulatory antigens in these cells.
To confirm this hypothesis two series of experiments
were performed. First, the HMGR gene was transfected
into Daudi cells. Transfected cells (Daudi-HMGR) ex-
pressed high levels of HMGR as shown by intracellular
staining with a specific mAb (Fig. 3 A) and acquired a
stronger capacity to stimulate TCR-
 
  
 
 cells (Fig. 3 B).
Treatment of Daudi-HMGR with mevastatin prevented
TCR-
 
  
 
 cell activation (Fig. 3 B). Importantly, when used
at suboptimal doses, mevastatin completely inhibited stim-
ulation by Daudi-HMGR only when added at least 12 h
before the assay, probably due to increased intracellular
HMGR levels.
Figure 2. Activation of TCR-   cells by tumor cells is dependent upon
the intracellular levels and activity of HMGR. (A) Mevastatin prevents re-
sponse of the TCR-   T cell clone G2B9 stimulated by Daudi and YMB-1
ligands, but has no effect on stimulation with IPP or PHA. Results show
TNF  mean release   SD. (B) HMGR protein levels are down-regulated
by farnesol or 7-DHC as detected by immunoprecipitation and Western
blot. (C) Treatment of Daudi cells with farnesol or 7-DHC prevents stim-
ulation of the G2B9 cells. In control experiments the same treatments of
Daudi cells did not affect stimulation with exogenous IPP.
Figure 3. HMGR-Daudi transfectants are potent stimulators. (A)
Daudi cells transfected with the HMGR gene express higher levels of
HMGR protein (bold line) than nontransfected Daudi cells (thin line).
No difference between the two cell types was detected using an irrelevant
mAb (dotted lines). (B) Daudi-HMGR cells (black bars) show increased
capacity to stimulate V 9/V 2 cells as compared with nontransfected
Daudi cells (white bars). Mevastatin was added at suboptimal doses (10
 M) 2, 6, or 12 h before incubation with T cells. Stimulation with IPP
was used as positive control.T
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In the second experimental series, Daudi cells were
treated with nBP, which inhibit FPP synthase and induce
accumulation of IPP, dimethylallylpyrophosphate, and ger-
anylpyrophosphate (14). These metabolites are substrates of
FPP synthase and are capable of activating TCR-   cells
when added exogenously to APCs (2, 3, 19). Two struc-
turally different nBP, PAM and ZOL, were tested at
equimolar concentrations and compared with etidronate, a
non-nBP that does not inhibit FPP synthase (14, 20).
ZOL- and PAM-treated APCs, but not etidronate-treated
APCs, stimulated TCR-   cells (online supplemental Fig.
S1). These results confirm previous studies performed with
other nBP (21, 22) and strongly suggest that accumulation
of phosphorylated metabolites within APCs is an important
event preceding stimulation of TCR-   cells.
A striking feature of the TCR-   cell stimulation with
exogenously added phosphorylated metabolites is a re-
quirement for the permanent presence of phosphorylated
ligands during the assay. Indeed, if bacterial ligands or IPP
are added to APCs at normal stimulatory doses and then
the cells are washed, the stimulatory capacity of APCs is
immediately lost, presumably because the activatory com-
pounds do not remain associated to the APC surface in a
stable and active form (23). To examine whether stimula-
tion with nBP follows the same rules as IPP, THP-1 cells
were pulsed for 2 h with ZOL, PAM, or IPP, and then ex-
tensively washed before being used to stimulate TCR-  
cells. After pulsing with ZOL and PAM, but not with IPP,
THP-1 cells retained a strong stimulatory capacity (Fig. 4
A). These data confirm the recent observation that the nBP
risedronate and PAM can be pulsed on primary monocytes
and on different tumor cell lines (22, 24). We also exam-
ined the kinetics of activation by pulsing Daudi cells with
ZOL or PAM at equimolar concentrations for various time
periods. ZOL induced its effects more rapidly than PAM
with 80% of maximal stimulation already observed after a
2-h pulse. This differential likely reflects the greater po-
tency of ZOL in inhibiting FPP synthase (20). However,
both nBP showed equal activity after a prolonged pulsing
time (Fig. 4 B), suggesting that they do not differ in their
mechanism of action.
As FPP synthase, the target of nBP, is present within
cells, it is likely that nBP must be internalized before be-
coming active. The fact that nBP are active after pulsing
and washing of APCs supports this possibility. To address
whether nBP internalization into the APCs is mandatory
for activation of V 9/V 2 T cells, pulsing was conducted
under conditions which inhibit pinocytosis and receptor-
mediated endocytosis. Daudi cells were pulsed with ZOL
either at 4 C (Fig. 4 C) or in the presence of monensin
(Fig. 4 D). Both conditions strongly inhibited activation of
V 9/V 2 T cells by ZOL-pulsed APCs, while activation
by IPP was minimally affected (Fig. 4 D). In control exper-
iments ZOL vigorously stimulated TCR-   cells when in-
cluded after incubation at 4 C and for the entire period of
the assay (Fig. 4 C), demonstrating that the 4 C incubation
did not render the APCs poorly stimulatory. To obtain fur-
ther proof of internalization, Daudi cells were pulsed with
14C-labeled ZOL under the same experimental conditions.
14C-ZOL was taken up by cells during pulsing at 37 C, but
not at 4 C or in the presence of monensin (Fig. 4 E). To-
gether, these data show that internalization of ZOL is pre-
requisite for its activity, and establish its distinction from
IPP, which is active without being internalized (23).
These findings suggest that nBP activate TCR-   by
inducing intracellular accumulation of stimulatory metab-
olites, although it cannot be formally excluded that mim-
icry of IPP is also applying, at least in some cases. The hy-
pothesis based on the effects exerted by accumulating
metabolites was examined by incubating Daudi cells with
ZOL and mevastatin together. As shown in Fig. 4 F, mev-
astatin completely abolished activation of V 9/V 2 T cells
when added simultaneously with ZOL, but was only 50%
inhibitory when added 1 h later. Mevastatin was not in-
Figure 4. ZOL and PAM ac-
tivate TCR-   cells after inter-
nalization in the APCs and
accumulation of mevalonate
metabolites. (A) THP-1 cells
stimulate the T cell clone G2D7
after 2 h pulse (black bars) with
ZOL or PAM, but not with IPP.
Overnight incubation (white
bars) with PAM and ZOL was
used as positive control. Similar
results were obtained by measur-
ing IFN-  release and using a
second TCR V 9/V 2 clone
(data not depicted). (B) ZOL
( ) is faster than PAM ( ) in
inducing TCR-   cell stimulatory ligands in Daudi cells. (C) ZOL requires cellular internalization to become stimulatory. Daudi cells were pulsed at 4
or at 37 C. In one control group ZOL was added back to exclude inhibitory effects of incubation at 4 C. (D) Daudi cells have reduced stimulatory ca-
pacities when incubated with monensin (Mon) and ZOL. IPP stimulation was used as positive control. (E) Intracellular uptake by Daudi cells of 14C-ZOL.
To exclude surface binding, pulse with 14C-ZOL was also performed at 4 C or in the presence of monensin. (F) Mevastatin completely inhibits activation
only when added simultaneously with ZOL. Mevastatin was added to Daudi cells together with ZOL, 1 or 3 h later. 3 h after ZOL, Daudi cells were
washed and T cells were added. Mevastatin was added back to keep its concentration constant during the entire culture period. Supernatants were har-
vested 12 h later.T
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hibitory when added 3 h after ZOL, suggesting that accu-
mulation of the stimulatory ligands had already taken
place. These data accord with those showing that a pulse
with ZOL for 3 h is sufficient to induce maximal stimula-
tory activity in APCs (Fig. 4 B). The latter results exclude
that mevastatin is toxic, and further support the conclusion
that the inhibitory action of mevastatin depends upon its
prevention of accumulation of mevalonate metabolites
during a ZOL pulse.
To identify the metabolites important in tumor cell rec-
ognition, we undertook their biochemical purification and
examined their TCR-   stimulatory capacities. Daudi cell
extracts were incubated with 3H-labeled mevalonate, the
first metabolite in the mevalonate cascade, and the radioac-
tive downstream metabolic products were detected in
HPLC fractions with the same retention time as reference
3H-labeled IPP (Fig. 5, A–C). Importantly, the same frac-
tions (which elute at 15–16 min) were also capable of acti-
vating V 9/V 2 T cells (Fig. 5 E). Furthermore, the
TCR-   stimulatory capacity was sensitive to alkaline
phosphatase treatment (Fig. 5 D), as previously shown for
mycobacterial products activating V 9/V 2 T cells (15).
Mass spectrometry analysis of the HPLC purified and
TCR-   stimulatory fraction eluting at 15.5 min (Fig. 5 F)
confirmed the presence of a compound with the same mass
as IPP (Fig. 5 F, insert).
As the mevalonate pathway is fundamental for cell sur-
vival and growth (25), all cells generate phosphorylated
mevalonate metabolites. Therefore, given the presence of
the appropriate adhesion and presentation molecules, it is
possible that all cells treated with nBP can stimulate TCR-
   cells. This hypothesis was tested by pulsing a variety of
tumor cell lines derived from different tissues with ZOL
and assaying their subsequent capacity to stimulate V 9/
V 2 T cells. Tumor cell lines established from distinct tis-
sues, as well as primary human lung fibroblasts, were used
as APCs either in the presence of IPP or after ZOL pulsing.
All tested lines, although with clear differences, were capa-
ble of activating TCR-   cells under both stimulatory
conditions (online supplemental Table S2). Thus, cells
from many different tissues have the capacity to present ac-
cumulated phosphorylated ligands in a stimulatory manner
to TCR-   cells. These findings indicate that presentation
of endogenous and exogenous ligands involves nonpoly-
morphic molecules with a wide tissue distribution.
Recognition of cells which overproduce nonpeptidic
phosphorylated metabolites generated by the mevalonate
pathway may allow the immune system to target cells with
significant metabolic abnormalities. This strategy has the
following important advantages. First, mevalonate interme-
diates are necessary for sterol synthesis, cell growth, and
membrane integrity, and thus tumor cells which up-regu-
late this pathway become more visible to the immune sys-
tem. Second, an alternative pathway for production of FPP
does not exist in mammalian cells (26) and this prevents se-
lection of negative mutants escaping immunosurveillance.
Third, the intracellular concentration of isoprenoids is finely
controlled by HMGR levels, which is one of the most
tightly regulated enzymes in mammalian cells (25). Several
signals such as cholesterol levels (27), insulin and thyroid
hormones (28), retinoids (29), and cell stress (30) contribute
toward increasing HMGR levels and the generation of me-
valonate pathway products. Accumulation of these metabo-
lites in excess of physiological levels represents the alarm
signal for activating TCR-   lymphocytes. Importantly,
this accumulation can be induced in vivo by using bisphos-
phonate drugs, such as ZOL, which are already in clinical
use. Tumor targeting of these drugs may provide a novel
approach to tumor immunotherapy that exploits the killing
capacity and the ligand specificity of TCR-   cells.
What is the immunological value of this unique type of
antigen recognition? It offers a general mechanism whereby
one T cell population could survey all tissues for both nor-
mal and transformed cells that are metabolically altered in
the mevalonate pathway. Furthermore, the same strategy
also carries the advantage of functioning as a surveillance
system for bacterial infection (6). It remains to be investi-
gated which type of evolutionary benefit this property has
endowed primates, the only order of mammals using this
unique immunological surveillance mechanism.
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Figure 5. The intracellular Daudi compounds activating TCR-   cells
are metabolites of the mevalonate pathway. (A–C) The stimulatory Daudi
ligands have the same retention time as IPP. Panel A shows the radioac-
tive compounds generated with Daudi cell extracts after addition of 3H-
mevalonic acid, panel B the reference 3H-IPP, panel C the reference 3H-
mevalonic acid (3H-Mev). (D) The stimulatory ligands present in Daudi
cell extracts are phosphatase sensitive. The semipurified material was
treated with alkaline phosphatase (AP) and then tested in TCR-   cell
stimulation assays. IPP treated identically was used as positive control for
AP activity. (E) Bioactivity of TCR-   stimulatory ligands from Daudi
cells. HPLC fractions were tested at a final dilution of 1:12 using THP-1
cells as APCs and the T cell clone G2B9. (F) Ion-spray Mass spectrometry
of the most active fraction from panel E. The arrow indicates the mass of
IPP. The insert shows the mass of reference IPP.T
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